ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates Novembro 29, 2017
ProQR to Present at the Annual Piper Jaffray Healthcare Conference Press release LEIDEN, the Netherlands, Nov. Novembro 21, 2017
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares Press release LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Novembro 14, 2017
ProQR Announces Proposed Public Offering of Ordinary Shares Press release LEIDEN, the Netherlands, Nov. Novembro 13, 2017
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness Press release Key Updates Novembro 13, 2017
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates Novembro 09, 2017
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Outubro 31, 2017
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Outubro 24, 2017